STOCK TITAN

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences earnings

Daré Bioscience (NASDAQ: DARE), a women's health innovation company, has announced it will host a conference call and webcast on November 14, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 financial results and provide a company update. The financial results will be released after market close on the same day. Participants can join via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (international) using conference ID 6400145. A webcast will be available on the company's investor relations website and archived until November 28, 2024.

Daré Bioscience (NASDAQ: DARE), un'azienda innovativa nel settore della salute femminile, ha annunciato che terrà una conferenza telefonica e un webcast il 14 novembre 2024 alle 16:30 ora orientale per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento sull'azienda. I risultati finanziari saranno resi noti dopo la chiusura del mercato lo stesso giorno. I partecipanti possono unirsi tramite telefono al (646) 307-1963 (U.S.) o (800) 715-9871 (internazionale) utilizzando l'ID conferenza 6400145. Un webcast sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda e sarà archiviato fino al 28 novembre 2024.

Daré Bioscience (NASDAQ: DARE), una empresa innovadora en salud femenina, ha anunciado que llevará a cabo una llamada de conferencia y un webcast el 14 de noviembre de 2024 a las 4:30 p.m. Hora del Este para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización de la empresa. Los resultados financieros se darán a conocer después del cierre del mercado el mismo día. Los participantes pueden unirse por teléfono al (646) 307-1963 (EE. UU.) o al (800) 715-9871 (internacional) utilizando el ID de conferencia 6400145. Un webcast estará disponible en el sitio web de relaciones con inversionistas de la empresa y se archivará hasta el 28 de noviembre de 2024.

Daré Bioscience (NASDAQ: DARE), 여성 건강 혁신 회사,가 2024년 11월 14일 오후 4시 30분 동부 표준시에 전화 회의 및 웹캐스트를 개최한다고 발표했습니다. 이는 2024년 3분기 재무 결과를 논의하고 회사 업데이트를 제공하기 위한 것입니다. 재무 결과는 같은 날 시장 마감 후 발표됩니다. 참가자는 전화 (646) 307-1963 (미국) 또는 (800) 715-9871 (국제)로 회의 ID 6400145를 사용하여 참여할 수 있습니다. 웹캐스트는 회사의 투자자 관계 웹사이트에서 이용 가능하며 2024년 11월 28일까지 아카이브됩니다.

Daré Bioscience (NASDAQ: DARE), une entreprise innovante dans le domaine de la santé des femmes, a annoncé qu'elle organisera une conférence téléphonique et un webcast le 14 novembre 2024 à 16h30, heure de l'Est, pour discuter de ses résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur l'entreprise. Les résultats financiers seront publiés après la clôture des marchés le même jour. Les participants peuvent rejoindre par téléphone au (646) 307-1963 (États-Unis) ou au (800) 715-9871 (international) en utilisant l'ID de conférence 6400145. Un webcast sera disponible sur le site Web des relations avec les investisseurs de l'entreprise et sera archivé jusqu'au 28 novembre 2024.

Daré Bioscience (NASDAQ: DARE), ein innovatives Unternehmen im Bereich Frauengesundheit, hat angekündigt, am 14. November 2024 um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abzuhalten, um die finanziellen Ergebnisse des dritten Quartals 2024 zu erörtern und ein Unternehmensupdate bereitzustellen. Die finanziellen Ergebnisse werden am selben Tag nach Börsenschluss veröffentlicht. Teilnehmer können sich telefonisch unter (646) 307-1963 (USA) oder (800) 715-9871 (international) unter Verwendung der Konferenz-ID 6400145 einwählen. Ein Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein und bis zum 28. November 2024 archiviert werden.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast.

To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 6400145. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com and available for replay until November 28, 2024.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.

The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra®, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Daré’s full portfolio of women’s health product candidates and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré's CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.


FAQ

When will Daré Bioscience (DARE) release its Q3 2024 earnings?

Daré Bioscience will release its Q3 2024 financial results after market close on Thursday, November 14, 2024.

How can I access Daré Bioscience's (DARE) Q3 2024 earnings call?

You can access the call by dialing (646) 307-1963 (U.S.) or (800) 715-9871 (international) with conference ID 6400145, or via webcast at http://ir.darebioscience.com.

What time is Daré Bioscience's (DARE) Q3 2024 earnings call?

The earnings call and webcast will take place at 4:30 p.m. Eastern Time on Thursday, November 14, 2024.

How long will Daré Bioscience's (DARE) Q3 2024 earnings webcast be available?

The webcast will be archived on the company's investor relations website until November 28, 2024.

Dare Bioscience, Inc.

NASDAQ:DARE

DARE Rankings

DARE Latest News

DARE Stock Data

28.45M
8.56M
1.59%
7.59%
0.34%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO